Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase

被引:82
作者
Guo, Song [1 ,2 ]
Olesen, Jes [1 ,2 ]
Ashina, Messoud [1 ,2 ]
机构
[1] Univ Copenhagen, Fac Hlth & Med Sci, Glostrup Hosp, Danish Headache Ctr, DK-2600 Glostrup, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Glostrup Hosp, Dept Neurol, DK-2600 Glostrup, Denmark
关键词
migraine; cilostazol; headache; cyclic adenosine monophosphate; phosphodiesterase inhibitor; GENE-RELATED PEPTIDE; CEREBRAL-ARTERIES; ADENYLATE-CYCLASE; PACAP RECEPTOR; NITRIC-OXIDE; SILDENAFIL; CGRP; EXPRESSION; TADALAFIL; HEADACHE;
D O I
10.1093/brain/awu244
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The initiating mechanisms of migraine attacks are very complex but may involve the cyclic AMP signalling pathway. It is unknown whether intracellular cyclic AMP accumulation induces migraine attacks. We investigated whether administration of cilostazol, which causes cyclic AMP accumulation, may induce migraine attacks. We included 14 migraine patients without aura in a double-blind, placebo-controlled crossover study. All participants received oral cilostazol or placebo on two separate days. We recorded migraine headache characteristics, associated symptoms and time of rescue medication intake using a questionnaire. Cilostazol induced delayed migraine-like attacks in 12 patients (86%) compared with two (14%) patients after placebo (P = 0.002). The median time to onset for migraine-like attacks was 6 h (range 3-11 h). Patients reported that the attacks mimicked their usual migraine attacks and that cilostazol-induced attacks responded to their usual migraine treatment. Median time of medication intake was 6 h (range 4-11 h). The present study suggests that intracellular cyclic AMP accumulation plays a crucial role in migraine induction. This knowledge is a further step in our understanding of the intracellular pathway of migraine initiation.
引用
收藏
页码:2951 / 2959
页数:9
相关论文
共 42 条
[31]   ANALYSIS OF SERIAL MEASUREMENTS IN MEDICAL-RESEARCH [J].
MATTHEWS, JNS ;
ALTMAN, DG ;
CAMPBELL, MJ ;
ROYSTON, P .
BRITISH MEDICAL JOURNAL, 1990, 300 (6719) :230-235
[32]   Differences in phosphodiesterase 3A and 3B expression after ischemic insult [J].
Mitome-Mishima, Yumiko ;
Miyamoto, Nobukazu ;
Tanaka, Ryota ;
Oishi, Hidenori ;
Arai, Hajime ;
Hattori, Nobutaka ;
Urabe, Takao .
NEUROSCIENCE RESEARCH, 2013, 75 (04) :340-348
[33]   The Science of Stroke: Mechanisms in Search of Treatments [J].
Moskowitz, Michael A. ;
Lo, Eng H. ;
Iadecola, Costantino .
NEURON, 2010, 67 (02) :181-198
[34]   Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide [J].
Nordgaard, Julie C. ;
Kruse, Lars S. ;
Moller, Morten ;
Kruuse, Christina .
CEPHALALGIA, 2014, 34 (07) :503-513
[35]   Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells [J].
Odum, L ;
Petersen, LJ ;
Skov, PS ;
Ebskov, LB .
INFLAMMATION RESEARCH, 1998, 47 (12) :488-492
[36]   NITRIC-OXIDE IS A KEY MOLECULE IN MIGRAINE AND OTHER VASCULAR HEADACHES [J].
OLESEN, J ;
THOMSEN, LL ;
IVERSEN, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (05) :149-153
[37]   Phosphodiesterase-3B is expressed in proopiomelanocortin and neuropeptide Y neurons in the mouse hypothalamus [J].
Sahu, Maitrayee ;
Litvin, David G. ;
Sahu, Abhiram .
NEUROSCIENCE LETTERS, 2011, 505 (02) :93-97
[38]   The PACAP Receptor: A Novel Target for Migraine Treatment [J].
Schytz, Henrik W. ;
Olesen, Jes ;
Ashina, Messoud .
NEUROTHERAPEUTICS, 2010, 7 (02) :191-196
[39]   PACAP38 induces migraine-like attacks in patients with migraine without aura [J].
Schytz, Henrik Winther ;
Birk, Steffen ;
Wienecke, Troels ;
Kruuse, Christina ;
Olesen, Jes ;
Ashina, Messoud .
BRAIN, 2009, 132 :16-25
[40]   Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity [J].
Sudo, T ;
Tachibana, K ;
Toga, K ;
Tochizawa, S ;
Inoue, Y ;
Kimura, Y ;
Hidaka, H .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (04) :347-356